The week in pharma: action, reaction and insight – week to July 31, 2026
By Barbara Obstoj-Cardwell. Editor
M&A news last week saw Belgo-Dutch firm argenx announce a deal to acquire Forte Biosciences, and its FB102, for around $2.2 billion, and Johnson & Johnson inked a collaboration with Sail Biosciences including an option to buy the company. UK pharma major GSK announced better than expected 2nd-qtr financials and growth plans. Also, the US Food and Drug Administration (FDA) issued negative briefing documents on US biotech Capricor Therapeutics’ deramiocel for the treatment of Duchenne muscular dystrophy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze